Leland Gershell
Stock Analyst at Oppenheimer
(4.52)
# 265
Out of 5,182 analysts
160
Total ratings
48.34%
Success rate
32.51%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLYM Climb Bio | Maintains: Outperform | $10 → $18 | $9.50 | +89.47% | 2 | Apr 21, 2026 | |
| ARGX argenx SE | Maintains: Outperform | $1,060 → $1,014 | $783.74 | +29.38% | 8 | Apr 2, 2026 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $110 → $80 | $52.75 | +51.66% | 10 | Mar 18, 2026 | |
| ENGN enGene Therapeutics | Maintains: Outperform | $33 → $30 | $7.20 | +316.67% | 4 | Mar 11, 2026 | |
| OCGN Ocugen | Initiates: Outperform | $10 | $1.70 | +488.24% | 1 | Mar 11, 2026 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $125 → $145 | $87.16 | +66.36% | 3 | Mar 9, 2026 | |
| CALC CalciMedica | Maintains: Outperform | $20 → $10 | $0.59 | +1,594.63% | 6 | Mar 5, 2026 | |
| AARD Aardvark Therapeutics | Maintains: Outperform | $35 → $21 | $5.52 | +280.43% | 2 | Mar 2, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $98 → $95 | $53.81 | +76.56% | 4 | Feb 24, 2026 | |
| ASND Ascendis Pharma | Maintains: Outperform | $246 → $262 | $226.66 | +15.59% | 13 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $283 | $57.18 | +394.93% | 1 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $54 | $35.10 | +53.85% | 6 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $24 | $14.27 | +68.19% | 4 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $6.12 | +194.12% | 6 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $36 | $13.50 | +166.67% | 7 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $73 → $87 | $38.62 | +125.27% | 8 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $28.75 | +178.26% | 1 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $61 | $74.52 | -18.14% | 3 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $490 | $308.51 | +58.83% | 8 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $5.63 | +255.56% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $110 | $85.20 | +29.11% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $31 | $23.77 | +30.42% | 11 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $100 | $1.29 | +7,651.94% | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $135 → $147 | $241.79 | -39.20% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $50 | $2.34 | +2,036.75% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $28.62 | +85.19% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.48 | +245.32% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30,000 → $5,000 | $2.21 | +226,144.34% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $4.99 | +401.00% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $29.27 | -0.92% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $14.42 | +142.72% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 | $17.93 | +1,573.17% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $0.93 | +2,050.54% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $1.86 | +598.92% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $4.21 | +2,750.36% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $6.06 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $31.26 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $13.93 | - | 5 | Mar 31, 2020 |
Climb Bio
Apr 21, 2026
Maintains: Outperform
Price Target: $10 → $18
Current: $9.50
Upside: +89.47%
argenx SE
Apr 2, 2026
Maintains: Outperform
Price Target: $1,060 → $1,014
Current: $783.74
Upside: +29.38%
Soleno Therapeutics
Mar 18, 2026
Maintains: Outperform
Price Target: $110 → $80
Current: $52.75
Upside: +51.66%
enGene Therapeutics
Mar 11, 2026
Maintains: Outperform
Price Target: $33 → $30
Current: $7.20
Upside: +316.67%
Ocugen
Mar 11, 2026
Initiates: Outperform
Price Target: $10
Current: $1.70
Upside: +488.24%
Dianthus Therapeutics
Mar 9, 2026
Maintains: Outperform
Price Target: $125 → $145
Current: $87.16
Upside: +66.36%
CalciMedica
Mar 5, 2026
Maintains: Outperform
Price Target: $20 → $10
Current: $0.59
Upside: +1,594.63%
Aardvark Therapeutics
Mar 2, 2026
Maintains: Outperform
Price Target: $35 → $21
Current: $5.52
Upside: +280.43%
BioMarin Pharmaceutical
Feb 24, 2026
Maintains: Outperform
Price Target: $98 → $95
Current: $53.81
Upside: +76.56%
Ascendis Pharma
Feb 12, 2026
Maintains: Outperform
Price Target: $246 → $262
Current: $226.66
Upside: +15.59%
Dec 23, 2025
Initiates: Outperform
Price Target: $283
Current: $57.18
Upside: +394.93%
Dec 8, 2025
Maintains: Outperform
Price Target: $22 → $54
Current: $35.10
Upside: +53.85%
Nov 14, 2025
Maintains: Outperform
Price Target: $23 → $24
Current: $14.27
Upside: +68.19%
Nov 7, 2025
Maintains: Outperform
Price Target: $18
Current: $6.12
Upside: +194.12%
Oct 21, 2025
Maintains: Outperform
Price Target: $32 → $36
Current: $13.50
Upside: +166.67%
Sep 30, 2025
Maintains: Outperform
Price Target: $73 → $87
Current: $38.62
Upside: +125.27%
Sep 3, 2025
Initiates: Outperform
Price Target: $80
Current: $28.75
Upside: +178.26%
Aug 6, 2025
Maintains: Outperform
Price Target: $60 → $61
Current: $74.52
Upside: -18.14%
Aug 4, 2025
Upgrades: Outperform
Price Target: $490
Current: $308.51
Upside: +58.83%
Jul 31, 2025
Initiates: Outperform
Price Target: $20
Current: $5.63
Upside: +255.56%
Jul 10, 2025
Maintains: Outperform
Price Target: $76 → $110
Current: $85.20
Upside: +29.11%
Jun 13, 2025
Maintains: Outperform
Price Target: $10 → $31
Current: $23.77
Upside: +30.42%
Mar 24, 2025
Initiates: Outperform
Price Target: $100
Current: $1.29
Upside: +7,651.94%
Nov 8, 2024
Maintains: Outperform
Price Target: $135 → $147
Current: $241.79
Upside: -39.20%
Nov 5, 2024
Reiterates: Outperform
Price Target: $50
Current: $2.34
Upside: +2,036.75%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $28.62
Upside: +85.19%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.48
Upside: +245.32%
Sep 3, 2024
Maintains: Outperform
Price Target: $30,000 → $5,000
Current: $2.21
Upside: +226,144.34%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $4.99
Upside: +401.00%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $29.27
Upside: -0.92%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $14.42
Upside: +142.72%
Apr 9, 2024
Maintains: Outperform
Price Target: $300
Current: $17.93
Upside: +1,573.17%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $0.93
Upside: +2,050.54%
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.86
Upside: +598.92%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $4.21
Upside: +2,750.36%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $6.06
Upside: -
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $31.26
Upside: -
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $13.93
Upside: -